NAYA Biosciences (NAYA) 10-Q 15 May 19 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 10, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	INVO Bioscience, Inc.,
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		155,421,112
Amendment Flag	false
Entity Central Index Key	0001417926
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current assets
Cash	$ 3,057,466	$ 212,243
Accounts receivable net	74,717	225,899
Inventory, net	51,685	43,513
Prepaid expense and other current assets	226,696	249,454
Total current assets	3,410,564	731,109
Property and equipment, net	81,709	34,446
Other Assets:
Capitalized patents, net	10,958	11,792
Total other assets	10,958	11,792
Total assets	3,503,231	777,347
Current liabilities
Accounts payable and accrued liabilities, including related parties	588,354	571,828
Accrued compensation	932,661	2,515,256
Deferred revenue	4,840,323	18,895
Note payable		131,722
Note payable - related party	35,000	97,743
Convertible notes, net of discount	196,883	157,039
Convertible notes, related party - net of discount	12,480	9,087
Total current liabilities	6,605,701	3,501,570
Commitments and contingencies
Stockholder's deficiency
Preferred Stock, $.0001 par value; 100,000,000 shares authorized; No shares issued and outstanding as of March 31, 2019 and December 31 2018, respectively	0	0
Common Stock, $.0001 par value; 200,000,000 shares authorized; 154,621,112 and 154,292,497 issued and outstanding as of March 31, 2019 and December 31, 2018, respectively	15,461	15,429
Additional paid-in capital	19,061,861	18,981,570
Accumulated deficit	(22,179,792)	(21,721,222)
Total stockholder's deficiency	(3,102,470)	(2,724,223)
Total liabilities and stockholders' deficiency	$ 3,503,231	$ 777,347

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Preferred Stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized	100,000,000	100,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common Stock, shares authorized	200,000,000	200,000,000
Common Stock, shares issued	154,621,112	154,292,497
Common Stock, shares outstanding	154,621,112	154,292,497

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue	$ 189,432	$ 104,140
Cost of Goods Sold:	10,978	14,424
Gross Margin	178,454	89,716
Selling, general and administrative expenses	527,565	229,999
Total operating expenses	527,565	229,999
Loss from operations	(349,111)	(140,283)
Interest expense	109,459	4,440
Total other (income) expenses	109,459	4,440
Loss before income taxes	(458,570)	(144,723)
Provisions for income taxes	0	0
Net Loss	$ (458,570)	$ (144,723)
Basic net loss per weighted average shares of common stock (in Dollars per share)	$ 0	$ 0
Diluted net loss per weighted average shares of common stock (in Dollars per share)	$ 0	$ 0
Basic weighted average number of shares of common stock (in Shares)	154,102,856	143,340,969
Diluted weighted average number of shares of common stock (in Shares)	154,102,856	143,340,969

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2017	$ 14,213	$ 13,638,806	$ (18,645,131)	$ (4,992,112)
Balance (in Shares) at Dec. 31, 2017	142,132,374
Common stock issued for cash	$ 26	46,974		47,000
Common stock issued for cash (in Shares)	260,000
Common stock issued to employees	$ 120	137,880		138,000
Common stock issued to employees (in Shares)	1,200,000
Common stock issued for services	$ 35	43,629		$ 43,664
Common stock issued for services (in Shares)	352,326			352,326
Net loss			(144,723)	$ (144,723)
Balance at Mar. 31, 2018	$ 14,394	13,867,289	(18,789,854)	(4,908,171)
Balance (in Shares) at Mar. 31, 2018	143,944,700
Balance at Dec. 31, 2018	$ 15,429	18,981,570	(21,721,222)	$ (2,724,223)
Balance (in Shares) at Dec. 31, 2018	154,292,497			154,292,497
Common stock issued for services	$ 6	26,594		$ 26,600
Common stock issued for services (in Shares)	60,000
Common stock issued to service providers	$ 26	53,697		53,723
Common stock issued to service providers (in Shares)	268,615
Net loss			(458,570)	(458,570)
Balance at Mar. 31, 2019	$ 15,461	$ 19,061,861	$ (22,179,792)	$ (3,102,470)
Balance (in Shares) at Mar. 31, 2019	154,621,112			154,621,112

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (458,570)	$ (144,723)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Non-cash stock compensation issued for services	26,600	181,664
Depreciation and amortization	1,971	1,134
Amortization of discount on notes payable	93,237	0
Changes in assets and liabilities:
Accounts receivable	151,182	(24,160)
Inventories	(8,172)	3,939
Prepaid expenses and other current assets	22,758	(12,523)
Deferred revenue	4,821,428	0
Accounts payable and accrued expenses	20,249	(124,884)
Accrued compensation	(1,582,595)	82,200
Net cash provided by (used in) operating activities	3,088,088	(37,353)
Cash from investing activities:
Payments to acquire property, plant and equipment	(48,400)	0
Net cash used in investing activities	(48,400)	0
Cash from financing activities:
Cash paid for related party notes payable	(62,743)	0
Cash paid for notes payable	(131,722)	0
Proceeds from the sale of common stock	0	47,000
Net cash (used in) provided by financing activities	(194,465)	47,000
Increase in cash and cash equivalents	2,845,223	9,647
Cash and cash equivalents at beginning of period	212,243	25,759
Cash and cash equivalents at end of period	3,057,466	35,406
Cash paid during the period for:
Interest	9,879	0
Taxes	912	912
Common stock issued for conversion of notes payable and accrued interest	$ 53,723	$ 0

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1 – Basis of Presentation The accompanying unaudited condensed consolidated balance sheets as of March 31, 2019 and December 31, 2018, the condensed consolidated statements of operations, stockholders’ deficiency and cash flows for the three months ended March 31, 2019 and 2018 of INVO Bioscience, Inc. (the “Company”), and the related information contained in these notes have been prepared by management and are unaudited. In the opinion of management, all adjustments (which include normal recurring and nonrecurring items) necessary to present fairly the Company’s financial position, results of operations and cash flows in conformity with generally accepted accounting principles for the periods presented have been made. Interim operating results are not necessarily indicative of operating results for a full year. The preparation of our unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Certain information and note disclosures normally included in the Company’s annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2018 Annual Report on Form 10-K previously filed by the Company with the Securities and Exchange Commission (SEC). The Company considers events or transactions that have occurred after the unaudited condensed consolidated balance sheet date of March 31, 2019, but prior to the filing of the unaudited condensed consolidated financial statements with the SEC on this Quarterly Report on Form 10-Q, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure, as applicable. Subsequent events have been evaluated through the date of the filing of this Quarterly Report on Form 10-Q with the SEC.

Note 2 - Recent Accounting Pron

Note 2 - Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	Note 2 – Recent Accounting Pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASUs”) to the FASB’s Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. ASUs not listed below were assessed and determined not to be applicable or are expected to have minimal impact on the Company’s consolidated financial position and results of operations. Recently Adopted Accounting Pronouncements In February 2016, FASB issued ASU 2016-02, Leases (“ASU 2016-02”). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The adoption of the new standard did not have an impact on the Company’s consolidated financial statements.

Note 3 - Going Concern

Note 3 - Going Concern	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	Note 3 – Going Concern On January 14, 2019, INVO Bioscience entered into a distribution agreement (the “Distribution Agreement”) with Ferring International Center S.A. (“Ferring”) granted to Ferring exclusive licensing rights to sublicense the Company’s INVOcell together with the retention device. Under the terms of the Distribution Agreement, Ferring was obligated to make an initial payment to the Company of $5,000,000 upon satisfaction of certain closing conditions. The Company received the initial $5 million cash payment received upon the execution of the Ferring distribution agreement in January 2019 and as a result believes its cash on hand will be sufficient to fund its current debt obligations, estimated capital expenditures and working capital needs for the next twelve to eighteen months.

Note 4 - Inventory

Note 4 - Inventory	3 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Note 4 – Inventory As of March 31, 2019 and December 31, 2018, the Company recorded the following inventory balances: March 31, 2019 December 31, 2018 Work in Process $ 42,428 $ 30,689 Finished Goods 9,257 12,824 Total Inventory , net $ 51,685 $ 43,513

Note 5 - Property and Equipment

Note 5 - Property and Equipment	3 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 5 – Property and Equipment The estimated useful lives and accumulated depreciation for furniture, equipment and software are as follows as of March 31, 2019 and December 31, 2018: Estimated Useful Life Molds 3 to 7 years March 31, 2019 December 31, 2018 Manufacturing Equipment- Molds $ 118,763 $ 70,363 Accumulated Depreciation (37,054 ) (35,917 ) Total $ 81,709 $ 34,446 During the three months ended March 31, 2018 and 2017 the Company recorded depreciation expense of $1,137 and $0, respectively. The Company began shipping its new retention device in August 2018 which triggered the start of depreciating our retention device mold during the current quarter.

Note 6 - Patents

Note 6 - Patents	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Intangible Assets Disclosure [Text Block]	Note 6 – Patents As of March 31, 2019 and December 31, 2018, the Company recorded the following patent balances: March 31, 2019 December 31, 2018 Total Patents $ 77,743 $ 77,743 Accumulated Amortization (66,785 ) (65,951 ) Patent costs, net $ 10,958 $ 11,792 During the three ended March 31, 2019 and 2018, the Company recorded $834 and $1,134 in amortization expenses respectively. Estimated amortization expense as of March 31, 2019 is as follows: Years ended December 31, 2019 $ 4,536 2020 1,809 2021 1,809 2022 and thereafter 2,804 Total $ 10,958

Note 7 - Notes Payable

Note 7 - Notes Payable	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Long-term Debt [Text Block]	Note 7 – Notes Payable Notes Payable In August 2016, INVO Bioscience converted a long time vendor’s outstanding accounts payable balance of $131,722 into a Promissory Note with a three year term that accrues interest at 5% per annum. The note provides for interest only payments on the first and second anniversaries of the note. The note is payable in full along with any outstanding accrued interest on August 9, 2019. The Company has the right to prepay the note at any time without a premium or penalty which it did in January 2019. The interest on this note for the three months ended March 31, 2019 and 2018 were $489 and $1,647, respectively. The Note and all accrued interest was paid in full and as of March 31, 2019, the balance is $0. 2018 Convertible Notes Payable In April and May 2018, the Company issued convertible notes (the “2018 Convertible Notes”) payable to investors’ in the aggregate principal amount of $895,000. The 2018 Convertible Notes accrue interest at the rate of 9% per annum which is paid in stock. 2018 Convertible Notes with an aggregate principal amount of $550,000 are due on January 30, 2021, and 2018 Convertible Notes with an aggregate principal amount of $345,000 are due on March 31, 2021. The notes are convertible into shares of common stock at a price of $0.20 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes can elect to convert the notes in shares of our common stock at a price equal to 75% of the price paid per share in such subsequent equity financing. During the fourth quarter of 2018, three note holders converted their notes with a value of $200,000 into 1,055,415 shares of common stock. During the three months ended March 31, 2019, a note holder converted principal and accrued interest of $50,000 and $3,723, respectively, into 268,615 shares of common stock. The Company calculated a beneficial conversion feature of the 2018 Convertible Notes based on ASU 17-11 in the form of a discount of $895,000; $93,237 and $0 of this amount was amortized to interest expense during the three months ended March 31, 2019 and 2018, respectively, based on the three year term of the notes. $37,377 was also amortized for a note that was converted during the first quarter of 2019. In addition $14,870 and $0 of interest was expensed in the three months ended March 31, 2019 and 2018, respectively.

Note 8 - Notes Payable and Othe

Note 8 - Notes Payable and Other Related Party Transactions	3 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 8 – Notes Payable and Other Related Party Transactions On September 18, 2008, the Company entered into a related party transaction with Dr. Claude Ranoux. Dr. Ranoux was then the President, Director and Chief Scientific Officer of the Company; as of the date of this filing he is a Director. Dr. Ranoux had loaned funds to the Company to sustain its operations since January 5, 2007 (inception). Dr. Ranoux’s total original cumulative investment as of December 31, 2008 was $96,462, as of December 31, 2017 and 2016 it is $21,888 (“the Principal Amount”) in INVO Bioscience. On March 26, 2009, the Company and Dr. Ranoux agreed to re-write the agreement to a non-convertible note payable bearing interest at 5% per annum, the term of the note had been extended, and has been extended a couple of additional times, the current repayment date is October 31, 2018. The Company and Dr. Ranoux can jointly decide to repay the loan earlier without prepayment penalties. During the twelve months ended December 31, 2018 the outstanding balance of $21,888 was paid in full including all interest due, in 2017, $0 was repaid on the principal of the loan. On March 5, 2009, the Company entered into a related party transaction with Kathleen Karloff, the Chief Executive Officer and a Director of the Company. Ms. Karloff provided a short-term loan in the amount of $75,000 bearing interest at 5% per annum to the Company to fund operations. In May 2009, Ms. Karloff loaned to the Company an additional $13,000, making her total cumulative loan $88,000 as of December 31, 2011. This note was due on September 15, 2009, which has since been extended a few times to its current date of October 31, 2018. During the twelve months ended December 31, 2014, Ms. Karloff loaned the Company an additional $66,000 at an interest rate of 0% by entering into a note payable agreement in satisfaction of expenses incurred by her for amounts previously advanced to the Company. This note currently has the same expiration date as the others which is October 31, 2018. During the twelve months ended December 31, 2018 $91,257 was paid against the principal of the loan, in 2017, $0 was repaid on the principal of the loan. The principal balances of the loan was $62,743 and $154,000 as of December 31 2018 and 2017 respectively. The related interest for the twelve months ended December 31, 2018 and 2017 was $15,278 and $4,400 respectively. During the three months ended March 31, 2019, the Company paid the remaining balance due Ms. Karloff in the amount of $62,743. In December 2009, James Bowdring, the brother of Director Robert Bowdring invested $100,000 acquiring 666,667 shares of restricted common stock. In April 2011, the Company issued a new short term convertible note (“Q211 Note”) payable to James Bowdring in the amount of $50,000. The Note carries a 10% interest rate. The note has a current balance of $25,000. The Q211 Note is convertible into Common Stock of the Company at a conversion price of $0.03 per share, subject to adjustments. During the three months ended March 31, 2019, the Company accrued interest in the amount of $616 on the Q211 Note. In November 2011, the Company issued a new convertible note (“Q411 Note”) payable to James Bowdring in the amount of $10,000. The Q411 Note carries a 10% interest rate. The Q411 Note is convertible into Common Stock of the Company at a conversion price of $0.01 per share, subject to adjustments. During the three months ended March 31, 2019, the Company accrued interest in the amount of $247 on the Q411 Note. In May 2018, James Bowdring and his children participated in the “2018 Convertible Notes” offerings in the aggregate principal amount of $40,000. The 2018 Convertible Notes accrue interest at the rate of 9% per annum which is paid in stock. These Notes are due on March 31, 2021. The notes are convertible into shares of common stock at a price of $0.20 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes can elect to convert the notes in shares of our common stock at a price equal to 75% of the price paid per share in such subsequent equity financing. The Company has been renting our corporate office from Forty Four Realty Trust which is owned by James Bowdring, the brother of Director & Acting Chief Financial Officer, Robert Bowdring since November 2012. It is a month to month rental arrangement for what the Company believes is less than the fair market real estate rental rate for comparable leases. The current rent is $600 per month, or $7,200 annually. In addition the Company purchases stationary supplies and marketing items at discounted rates from Superior Printing & Promotions which is also owned by James Bowdring and is in the same building as our corporate office. INVO Bioscience spent $778 and $234 with Superior during the first three months of 2019 and 2018, respectively. Principal balances of the Related Party loans were as follows: March 31, 2019 December 31, 2018 James Bowdring Family - 2011 Notes 35,000 35,000 James Bowdring Family – 2018 Convertible Notes 40,000 40,000 Kathleen Karloff Note - 62,743 Less discount (27,520 ) (30,913 ) Total, net of discount $ 47,480 $ 106,830 Interest expense on the Related Party loans was $1,751 and $2,792 for the three months ended March 31, 2019 and 2018, respectively. Accounts payable and accrued liabilities balances include expenses reports for Ms. Karloff and Mr. Bowdring for expenses they paid for personally related to travel or normal business expenses. As of March 31, 2019 they were $1,762 and as of December 31, 2018, they were $1,676.

Note 9 - Stockholders_ Equity

Note 9 - Stockholders’ Equity	3 Months Ended
	Mar. 31, 2019
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 9 – Stockholders’ Equity Three Months Ended March 31, 2019 In January 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 60,000 shares of common stock with a fair value of $26,600 to service providers. In February 2019, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 268,615 shares of common stock for conversion of notes payable and accrued interest in the amount of $53,723. Three Months Ended March 31 , 201 8 In January and March 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company sold 260,000 shares of common stock to accredited investors in a private placement for cash of $47,000. In January 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 1,200,000 shares of common stock with a fair value of $138,000 to management and board members. In January and March 2018, pursuant to Section 4(a)(2) of the Securities Act, the Company issued 352,326 shares of common stock with a fair value of $43,664 to service providers.

Note 10 - Stock Options and War

Note 10 - Stock Options and Warrants	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block Supplement [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	Note 10 – Stock Options and Warrants As of March 31, 2019 and December 31, 2018, the Company does not have any outstanding or committed and unissued stock options or warrants.

Note 11 - Income Taxes

Note 11 - Income Taxes	3 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 11 – Income Taxes The Company has adopted ASC 740-10, which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The Company’s total deferred tax liabilities, deferred tax assets and deferred tax asset valuation allowances at March 31, 2019 and December 31, 2018 are as follows: March 31, 2019 December 31, 2018 Total deferred tax assets $ 4,240,000 $ 4,124,000 Less valuation allowance (4,240,000 ) (4,124,000 ) Total deferred tax liabilities - - Net deferred tax asset (liability) $ - $ - Realization of deferred tax assets is dependent on future earnings, if any, the timing and amount of which is uncertain. Those amounts are therefore presented on the Company’s balance sheets as a non-current asset. Utilization of the net operating loss carry forwards may be subject to substantial annual limitations, which may result in the expiration of net operating loss carry forwards before utilization.

Note 12 - Commitments and Conti

Note 12 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 12 – Commitments and Contingencies A) Operating Leases In November 2012, INVO Bioscience entered into a month-to-month rental agreement with Four Forty Realty Trust with for the space it requires. Four Forty Realty Trust is owned by investor James Bowdring, the brother of Director & Acting Chief Financial Officer Robert Bowdring. The annual rent under the agreement is $7,200 annually. B) Litigation There has been no change in the status of the litigation INVO Bioscience, Inc., and two of its directors have been involved in since 2010, defending litigation brought by investors in an alleged predecessor of INVO Bioscience. On March 24, 2010, INVO Bioscience, Inc. and its corporate affiliate, Bio X Cell, Inc., Claude Ranoux, and Kathleen Karloff were served an Amended Complaint, the original of which was filed on December 31, 2009 at the Suffolk Superior Court Business Litigation Session by two terminated employees of Medelle Corporation (also named as a co-defendant but no longer active), who are also attorneys, and a former investor in and creditor of Medelle. These plaintiffs allege various claims of wrongdoing relating to the sale of assets of Medelle to Dr. Ranoux. Plaintiffs claim that Dr. Ranoux, Ms. Karloff, and Medelle (and therefore INVO Bioscience as an alleged successor corporation) violated alleged duties owed to plaintiffs in connection with the sale. Separate claims were also alleged against INVO Bioscience. Dr. Ranoux, Ms. Karloff, and INVO Bioscience have challenged these allegations, which they believe are baseless. The transfer of the assets of Medelle was professionally handled by an independent third party, after approval by the Medelle Board of Directors, representing a majority of its shareholders. Medelle’s Board voted to proceed with an assignment for the benefit of creditors (AFBC) and gave complete authority to the President & CEO at that time (neither Dr. Ranoux nor Ms. Karloff) to work with the third-party assignee and to get the best possible price for those assets. The third party was responsible for notifying all the appropriate parties and for filing notices in various professional publications and newspapers of Medelle’s intention to sell its assets. The third party also contacted numerous large medical device and bio-pharma companies to learn if they would be interested in acquiring the assets. After a private sale was deemed unlikely, the assignee of the assets elected to proceed with a sealed-bid auction of the assets. On the day of the auction, Dr. Ranoux submitted the only bid and was awarded the assets, upon full payment. During 2010, Dr. Ranoux, Ms. Karloff, and INVO Bioscience filed Motions to Dismiss as to all claims, pursuant to M.R.Civ. P. 12(b)(6). In a written Decision rendered on November 12, 2010, the judge dismissed all claims against INVO, Bio X Cell, and Ms. Karloff, and also dismissed the claims against Dr. Ranoux alleging civil conspiracy and breach of M.G.L. c. 93A. The judge denied Dr. Ranoux’s motion to dismiss the remaining breach of fiduciary duty and fraud claims. The plaintiffs allege in their Amended Complaint that Dr. Ranoux committed fraud by failing to inform them of the details of the Medelle auction. The claims against Dr. Ranoux that survived the November 2010 dismissal order were submitted to binding arbitration. On February 15, 2013, the mutually-agreed arbitrator ruled in favor of Dr. Ranoux. The award held that Dr. Ranoux did not withhold information about the auction of Medelle’s assets and expressed doubt that the plaintiffs would have invested the resources necessary to make a beneficial use of the assets. The arbitrator’s award then was confirmed by the Superior Court on August 21, 2013. The Superior Court’s confirmation of the award was affirmed on appeal on October 20, 2013 by the Massachusetts Appeals Court. The Massachusetts Supreme Judicial Court then denied further appellate review. On October 18, 2016, following motions and argument, the Superior Court issued a memorandum of decision and order denying plaintiffs’ motion for entry of default judgment and assessment of damages against Medelle and allowed the motion of INVO Bioscience, Bio X Cell, and Ms. Karloff for entry of final judgment of dismissal. The foregoing order was converted to a final judgment dismissing all claims against all defendants and entered on the docket on October 27, 2016. On November 28, 2016, plaintiffs filed an amended notice of appeal from the Superior Court’s decision of October 17, 2016 and the subsequent judgment entered on October 27, 2016. The appeal further challenges the order of dismissal from November, 2010. Plaintiffs did not appeal from the dismissal of the claims against Ms. Karloff, so the judgment in her favor is now final, leaving claims against INVO Bioscience, Bio X Cell, Medelle, and Dr. Ranoux. INVO Bioscience and Bio X Cell intend a vigorous opposition to the current appeal, consistent with their previous positions that no breach of duty occurred in the sale of Medelle’s assets. It is assumed that Dr. Ranoux will oppose the appeal as well. Outside of the above-mentioned litigation, neither INVO Bioscience nor Bio X Cell, our wholly-owned subsidiary, either directly or indirectly, are involved in any lawsuit outside the ordinary course of business, the disposition of which would have a material effect upon either our results of operation, financial position, or cash flows. C) Employee Agreements The Company is in the process of writing employment agreements for its current officers, executives and employees of the Company. D) Consulting Agreements The Company has a verbal agreement beginning in March, 2013 with its former CFO, Robert Bowdring, who is currently a Director & Acting Chief Financial Officer, to assist where necessary in the financial and administrative areas of the Company for compensation to be equivalent to the others working in the organization.

Note 13 - Contracts with Custom

Note 13 - Contracts with Customers	3 Months Ended
	Mar. 31, 2019
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	Note 13 – Contracts with Customers We have adopted ASC 606, Revenue from Contracts with Customers . Revenue Recognition Revenues for products, including: INVOcell ® TM In January, 2019 we announced a U.S. license and distribution agreement with Ferring International Center S.A. (“Ferring”) and as a result took a significant step to strengthen the Company that we believe will allow us to implement our overall business plan. We believe that this strategic partnership with a strong reproductive organization such as Ferring Pharmaceuticals will provide us with the necessary sales and marketing resources within the United States to expand the market and help reach all of those couples not receiving reproductive treatments today. The agreement calls for the issuance of an initial upfront payment of $5 million which we received upon the signing of the agreement and then subsequent licensing fee payment of $3,000,000 that will provide us with a source of non-dilutive financing to execute our plan. Under the terms of the agreement we can pursue developing international markets and as well as partnering and opening INVO-only reproductive centers within the U.S. market. We believe this major milestone and agreement is a critical step that allows the Company to implement its mission of expanding access to care in the fertility marketplace. Under the terms of the Distribution Agreement, Ferring completed its obligation to make an initial payment to the Company of $5,000,000 upon completion of the required closing conditions, including executed agreements from all current manufacturers of the Licensed Product that upon a material supply default by the Company, Ferring can assume a direct purchase relationship with such manufacturers. Ferring is obligated to make a second payment to the Company of $3,000,000 provided that the Company is successful in obtaining a five (5) day label enhancement from the FDA for the current incubation period for the Licensed Product at least three (3) years prior to the expiration of the term of the license for the Licensed Product and provided further that Ferring has not previously exercised its right to terminate the Distribution Agreement for convenience. In addition, the Company entered into a separate Distribution Agreement. The Distribution Agreement has an initial term expiring on December 31, 2025 and at the end of the initial term it may be terminated by the Company if Ferring fails to generate specified minimum revenues to the Company from the sale of the Licensed Product during the final two years of the initial term. The Ferring license was deemed to be a functional licenses that provide customers with a “right to access” to our intellectual property during the subscription period and, accordingly, revenue is recognized over a period of time, which is generally the subscription period. During the quarter ended March 31, 2019, the Company recognized $178,572 related to the Ferring license agreement. As of March 31, 2019 and December 31, 2018, the Company had deferred revenues of $4,840,323 and $18,895, respectfully. Sources of Revenue We have identified the following revenues disaggregated by revenue source: Domestic Physicians – direct sales of products concluded in January 2019 Domestic Distributor - sales to Ferring who then sells to physicians Domestic Licensing fee International Distributors – direct sales of products. For the three months ended March 31, 2019 and 2018 the source of revenue was derived from: March 31, 2019 March 31, 2018 Domestic Physicians $ 10,860 $ 104,140 Domestic Licensing & Distribution Fee 178,572 - Total revenue $ 189,432 $ 104,140 Contract Balances We incur agreement obligations on general customer purchase orders and e-mails that have been accepted but unfulfilled. Due to the short duration of time between order acceptance and delivery of the related product, we have determined that the balance related to these obligations is generally immaterial at any point in time. We monitor the value of orders accepted but unfulfilled at the close of each reporting period to determine if disclosure is appropriate. Warranty Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations. Commissions and Contract Costs We do not use or offer sales commissions of any type at this time. We generally do not incur incremental charges associated with securing agreements with customers which would require capitalization and recovery over the life of the agreement. Practical Expedients Our payment terms for sales direct to customers and distributors are substantially less than the one year collection period that falls within the practical expedient in determination of whether a significant financing component exists. Shipping and Handling Charges Fees charged to customers for shipping and handling of products are included as an offset to the costs for shipping and handling of products included as a component of cost of products. Taxes Collected from Customers As our products are used in another service and are exempt, to this point we have not collected taxes. If we were to collect taxes they would be on the value of transaction revenue and would be excluded from product revenues and cost of sales and would be accrued in current liabilities until remitted to governmental authorities. Effective Date and Transition Disclosures Adoption of the new standards related to revenue recognition did not have a material impact on our consolidated financial statements, and is not expected to have a material impact in future periods.

Note 14 - Subsequent Events

Note 14 - Subsequent Events	3 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 14 – Subsequent Events On April 24, 2019, the Company issued 800,000 shares of common stock in connection with the conversion of a note payable in the principal amount of $160,000. The Company has evaluated subsequent events through the date the financial statements were released and there were no others.

Note 4 - Inventory (Tables)

Note 4 - Inventory (Tables)	3 Months Ended
	Mar. 31, 2019
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	As of March 31, 2019 and December 31, 2018, the Company recorded the following inventory balances: March 31, 2019 December 31, 2018 Work in Process $ 42,428 $ 30,689 Finished Goods 9,257 12,824 Total Inventory , net $ 51,685 $ 43,513

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2019
Note 5 - Property and Equipment (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]	March 31, 2019 December 31, 2018 Manufacturing Equipment- Molds $ 118,763 $ 70,363 Accumulated Depreciation (37,054 ) (35,917 ) Total $ 81,709 $ 34,446
Estimated Useful Life [Member]
Note 5 - Property and Equipment (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]	The estimated useful lives and accumulated depreciation for furniture, equipment and software are as follows as of March 31, 2019 and December 31, 2018: Estimated Useful Life Molds 3 to 7 years

Note 6 - Patents (Tables)

Note 6 - Patents (Tables)	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	As of March 31, 2019 and December 31, 2018, the Company recorded the following patent balances: March 31, 2019 December 31, 2018 Total Patents $ 77,743 $ 77,743 Accumulated Amortization (66,785 ) (65,951 ) Patent costs, net $ 10,958 $ 11,792
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Estimated amortization expense as of March 31, 2019 is as follows: Years ended December 31, 2019 $ 4,536 2020 1,809 2021 1,809 2022 and thereafter 2,804 Total $ 10,958

Note 8 - Notes Payable and Ot_2

Note 8 - Notes Payable and Other Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	Principal balances of the Related Party loans were as follows: March 31, 2019 December 31, 2018 James Bowdring Family - 2011 Notes 35,000 35,000 James Bowdring Family – 2018 Convertible Notes 40,000 40,000 Kathleen Karloff Note - 62,743 Less discount (27,520 ) (30,913 ) Total, net of discount $ 47,480 $ 106,830

Note 11 - Income Taxes (Tables)

Note 11 - Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The Company’s total deferred tax liabilities, deferred tax assets and deferred tax asset valuation allowances at March 31, 2019 and December 31, 2018 are as follows: March 31, 2019 December 31, 2018 Total deferred tax assets $ 4,240,000 $ 4,124,000 Less valuation allowance (4,240,000 ) (4,124,000 ) Total deferred tax liabilities - - Net deferred tax asset (liability) $ - $ -

Note 13 - Contracts with Cust_2

Note 13 - Contracts with Customers (Tables)	3 Months Ended
	Mar. 31, 2019
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue [Table Text Block]	For the three months ended March 31, 2019 and 2018 the source of revenue was derived from: March 31, 2019 March 31, 2018 Domestic Physicians $ 10,860 $ 104,140 Domestic Licensing & Distribution Fee 178,572 - Total revenue $ 189,432 $ 104,140

Note 3 - Going Concern (Details

Note 3 - Going Concern (Details) - USD ($) $ in Millions	Jan. 14, 2019	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Proceeds from License Fees Received	$ 5	$ 5

Note 4 - Inventory (Details) -

Note 4 - Inventory (Details) - Schedule of Inventory, Current - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Schedule of Inventory, Current [Abstract]
Work in Process	$ 42,428	$ 30,689
Finished Goods	9,257	12,824
Total Inventory, net	$ 51,685	$ 43,513

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Property, Plant and Equipment [Abstract]
Depreciation	$ 1,137	$ 0

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment (Details) - Property, Plant and Equipment, Estimated Useful Life	3 Months Ended
	Mar. 31, 2019
Minimum [Member]
Property, Plant and Equipment [Line Items]
Molds	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Molds	7 years

Note 5 - Property and Equipme_5

Note 5 - Property and Equipment (Details) - Property, Plant and Equipment - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Total	$ 81,709	$ 34,446
Tools, Dies and Molds [Member]
Property, Plant and Equipment [Line Items]
Manufacturing Equipment- Molds	118,763	70,363
Accumulated Depreciation	$ (37,054)	$ (35,917)

Note 6 - Patents (Details)

Note 6 - Patents (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Disclosure Text Block [Abstract]
Amortization of Intangible Assets	$ 834	$ 1,134

Note 6 - Patents (Details) - Sc

Note 6 - Patents (Details) - Schedule of Finite-Lived Intangible Assets - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Schedule of Finite-Lived Intangible Assets [Abstract]
Total Patents	$ 77,743	$ 77,743
Accumulated Amortization	(66,785)	(65,951)
Patent costs, net	$ 10,958	$ 11,792

Note 6 - Patents (Details) - _2

Note 6 - Patents (Details) - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Abstract]
2019	$ 4,536
2020	1,809
2021	1,809
2022 and thereafter	2,804
Total	$ 10,958	$ 11,792

Note 7 - Notes Payable (Details

Note 7 - Notes Payable (Details) - USD ($)	May 31, 2018	Aug. 31, 2016	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018
Converted Account Payable to Promissory Note [Member]
Note 7 - Notes Payable (Details) [Line Items]
Debt Instrument, Face Amount		$ 131,722
Debt Instrument, Term		3 years
Debt Instrument, Interest Rate, Stated Percentage		5.00%
Interest Expense, Debt			$ 1,647
The 2018 Convertible Notes [Member]
Note 7 - Notes Payable (Details) [Line Items]
Debt Instrument, Face Amount	$ 895,000
Debt Instrument, Interest Rate, Stated Percentage	9.00%
Interest Expense, Debt			$ 14,870		$ 0
Debt Instrument, Convertible, Terms of Conversion Feature	shares of common stock at a price of $0.20 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes can elect to convert the notes in shares of our common stock at a price equal to 75% of the price paid per share in such subsequent equity financing
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	$ 0.20
Debt Conversion, Original Debt, Amount				$ 200,000
Debt Conversion, Converted Instrument, Shares Issued (in Shares)			268,615	1,055,415
Debt Instrument, Unamortized Discount	$ 895,000
Amortization of Debt Discount (Premium)			$ 93,237		$ 0
Amortization of Debt Issuance Costs and Discounts			37,377
The 2018 Convertible Notes, Due January 30, 2021 [Member]
Note 7 - Notes Payable (Details) [Line Items]
Convertible Notes Payable	550,000
The 2018 Convertible Notes, Due March 31, 2021 [Member]
Note 7 - Notes Payable (Details) [Line Items]
Convertible Notes Payable	$ 345,000
Convertible Debt [Member] | Converted Account Payable to Promissory Note [Member]
Note 7 - Notes Payable (Details) [Line Items]
Convertible Debt, Current			0
Principal [Member] | The 2018 Convertible Notes [Member]
Note 7 - Notes Payable (Details) [Line Items]
Debt Conversion, Original Debt, Amount			50,000
Accrued Interest [Member] | The 2018 Convertible Notes [Member]
Note 7 - Notes Payable (Details) [Line Items]
Debt Conversion, Original Debt, Amount			$ 3,723

Note 8 - Notes Payable and Ot_3

Note 8 - Notes Payable and Other Related Party Transactions (Details) - USD ($)	Dec. 31, 2014	Dec. 28, 2009	Sep. 30, 2018	May 31, 2018	May 31, 2009	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2011	Nov. 30, 2011	Apr. 30, 2011	Mar. 26, 2009	Mar. 05, 2009
Note 8 - Notes Payable and Other Related Party Transactions (Details) [Line Items]
Due to Related Parties, Current						$ 12,480		$ 9,087
Debt Instrument, Interest Rate, Stated Percentage				9.00%
Repayments of Related Party Debt						62,743	$ 0
Debt Instrument, Face Amount				$ 40,000
Notes Payable, Related Parties						47,480		106,830
Interest Expense, Related Party						1,751	2,792
Debt Instrument, Convertible, Conversion Price (in Dollars per share)				$ 0.20
Debt Instrument, Convertible, Terms of Conversion Feature				The notes are convertible into shares of common stock at a price of $0.20 per share, provided, that if the Company completes a subsequent equity financing, the holders of the 2018 Convertible Notes can elect to convert the notes in shares of our common stock at a price equal to 75% of the price paid per share in such subsequent equity financing
Operating Leases, Rent Expense						7,200
President, Director, and Chief Scientific Officer [Member]
Note 8 - Notes Payable and Other Related Party Transactions (Details) [Line Items]
Due to Related Parties, Current									$ 96,462	$ 21,888
Debt Instrument, Interest Rate, Stated Percentage															5.00%
Repayments of Related Party Debt								21,888	0
Chief Executive Officer [Member]
Note 8 - Notes Payable and Other Related Party Transactions (Details) [Line Items]
Due to Related Parties, Current												$ 88,000
Debt Instrument, Interest Rate, Stated Percentage	0.00%															5.00%
Repayments of Related Party Debt						62,743		91,257	0
Debt Instrument, Face Amount																$ 75,000
Proceeds from Related Party Debt	$ 66,000				$ 13,000
Notes Payable, Related Parties						0		62,743	154,000
Interest Expense, Related Party								$ 15,278	$ 4,400
Immediate Family Member of Management or Principal Owner [Member]
Note 8 - Notes Payable and Other Related Party Transactions (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage													10.00%
Debt Instrument, Face Amount													$ 10,000
Interest Expense, Related Party						247
Debt Instrument, Convertible, Conversion Price (in Dollars per share)													$ 0.01
Immediate Family Member of Management or Principal Owner [Member] | Building [Member]
Note 8 - Notes Payable and Other Related Party Transactions (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals			$ 600
Operating Leases, Rent Expense, Net			$ 7,200
Operating Leases, Rent Expense						$ 778	$ 234
Charles Mulrey and Family [Member]
Note 8 - Notes Payable and Other Related Party Transactions (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)						1,676
Q2 Note [Member] | Immediate Family Member of Management or Principal Owner [Member]
Note 8 - Notes Payable and Other Related Party Transactions (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage														10.00%
Debt Instrument, Face Amount		$ 100,000												$ 50,000
Notes Payable, Related Parties											$ 25,000
Interest Expense, Related Party						$ 616
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares)		666,667
Debt Instrument, Convertible, Conversion Price (in Dollars per share)											$ 0.03

Note 8 - Notes Payable and Ot_4

Note 8 - Notes Payable and Other Related Party Transactions (Details) - Schedule of Related Party Transactions - USD ($)	Mar. 31, 2019	Dec. 31, 2018	May 31, 2018	Dec. 31, 2017
Related Party Transaction [Line Items]
Related Party Loans	$ 47,480	$ 106,830
Less discount	(27,520)	(30,913)
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Related Party Loans	0	62,743		$ 154,000
2011 Notes [Member] | Immediate Family Member of Management or Principal Owner [Member]
Related Party Transaction [Line Items]
Related Party Loans	35,000	35,000
The 2018 Convertible Notes [Member]
Related Party Transaction [Line Items]
Less discount			$ (895,000)
The 2018 Convertible Notes [Member] | Immediate Family Member of Management or Principal Owner [Member]
Related Party Transaction [Line Items]
Related Party Loans	$ 40,000	$ 40,000

Note 9 - Stockholders_ Equity (

Note 9 - Stockholders’ Equity (Details) - USD ($)	1 Months Ended			3 Months Ended
	Feb. 28, 2019	Jan. 31, 2019	Jan. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Note 9 - Stockholders’ Equity (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services		60,000			352,326
Stock Issued During Period, Value, Issued for Services		$ 26,600		$ 26,600	$ 43,664
Debt Conversion, Converted Instrument, Shares Issued	268,615
Debt Conversion, Original Debt, Amount	$ 53,723
Restricted Stock [Member] | Management and Board Members [Member]
Note 9 - Stockholders’ Equity (Details) [Line Items]
Stock Issued During Period, Value, Issued for Services			$ 138,000
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture			1,200,000
Private Placement [Member]
Note 9 - Stockholders’ Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues					260,000
Proceeds from Issuance or Sale of Equity					$ 47,000

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Schedule of Deferred Tax Assets and Liabilities [Abstract]
Total deferred tax assets	$ 4,240,000	$ 4,124,000
Less valuation allowance	(4,240,000)	(4,124,000)
Total deferred tax liabilities	0	0
Net deferred tax asset (liability)	$ 0	$ 0

Note 12 - Commitments and Con_2

Note 12 - Commitments and Contingencies (Details)	3 Months Ended
	Mar. 31, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
Operating Leases, Rent Expense	$ 7,200

Note 13 - Contracts with Cust_3

Note 13 - Contracts with Customers (Details) - USD ($)	Jan. 14, 2019	Mar. 31, 2019	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Proceeds from License Fees Received	$ 5,000,000	$ 5,000,000
Subsequent Licensing Fee Payment	$ 3,000,000
Deferred Revenue, Revenue Recognized		178,572
Deferred Revenue		$ 4,840,323	$ 18,895

Note 13 - Contracts with Cust_4

Note 13 - Contracts with Customers (Details) - Disaggregation of Revenue - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Disaggregation of Revenue [Line Items]
Revenue	$ 189,432	$ 104,140
Domestic Physicians [Member]
Disaggregation of Revenue [Line Items]
Revenue	10,860	104,140
Domestic Licensing & Distribution Fee [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 178,572	$ 0

Note 14 - Subsequent Events (De

Note 14 - Subsequent Events (Details) - Subsequent Event [Member]	Apr. 24, 2019USD ($)shares
Note 14 - Subsequent Events (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued | shares	800,000
Debt Conversion, Original Debt, Amount | $	$ 160,000